Subtype
Pancreatic Neoplasm
CI-CAN-00001356Explore in graph →
Non-malignant988 active trials8 approved drugs63 evidence items
Loading cancer entity…
Subtype
CI-CAN-00001356Explore in graph →
Clinical trials
4,217 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02307500 | Regorafenib in Patients With Metastatic Solid Tumors Who Have Progressed After Standard Therapy(RESOUND) | completed | Phase 2 | 82 | Istituto Clinico HumanitasOTHER | 1 | Sep 10, 2022 | clinicaltrials |
| NCT01547260 | Lenalidomide and Gemcitabine as First-line Treatment in Patients With Pancreatic Cancer(LENAGEM) | completed | Phase 1 / Phase 2 | 34 | Maria LiljeforsOTHER | 1 | Aug 22, 2022 |
| clinicaltrials |
| NCT04769414 | Flouro-Gem in Adenocarcinoma of the Pancreas (GEFLUPAN) | completed | Phase 2 | 48 | Menoufia UniversityOTHER | 1 | Aug 8, 2022 | clinicaltrials |
| NCT01229943 | Everolimus and Octreotide Acetate With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors That Cannot Be Removed by Surgery | completed | Phase 2 | 150 | National Cancer Institute (NCI)NIH | 2 | Aug 4, 2022 | clinicaltrials |
| NCT02080221 | BrUOG 292: FOLFOX-A For Metastatic Pancreatic Cancer: A Phase II Brown University Oncology Research Group Trial | completed | Phase 2 | 50 | Brown UniversityOTHER | 1 | Aug 1, 2022 | clinicaltrials |
| NCT02358356 | Capecitabine ON Temozolomide Radionuclide Therapy Octreotate Lutetium-177 NeuroEndocrine Tumours Study(CONTROL NETS) | completed | Phase 2 | 75 | Australasian Gastro-Intestinal Trials GroupNETWORK | 1 | Jul 5, 2022 | clinicaltrials |
| NCT03086369 | A Study of Nab-Paclitaxel and Gemcitabine With or Without Olaratumab (LY3012207) in Participants With Metastatic Pancreatic Cancer | completed | Phase 1 / Phase 2 | 184 | Eli Lilly and CompanyINDUSTRY | 3 | Jun 28, 2022 | clinicaltrials |
| NCT02022033 | BrUOG 295: Adjuvant FOLFOX-A For Resected Pancreatic Cancer: A Phase II Brown University Oncology Research Group Trial | completed | Phase 2 | 25 | Brown UniversityOTHER | 1 | Jun 1, 2022 | clinicaltrials |
| NCT02704156 | SBRT Plus Pembrolizumab and Trametinib for Pancreatic Cancer | completed | Phase 2 | 170 | Changhai HospitalOTHER | 1 | May 13, 2022 | clinicaltrials |
| NCT00710710 | Open, Randomized Phase II Trial to Investigate the Efficacy and Safety of the PLK-1 Inhibitor BI 2536 in Patients With Advanced, Unresectable Pancreatic Cancer | completed | Phase 2 | 89 | Boehringer IngelheimINDUSTRY | 2 | May 4, 2022 | clinicaltrials |
| NCT02080260 | A Study of Regorafenib in Advanced Pancreatic Cancer Patients | completed | Phase 2 | 20 | Wake Forest University Health SciencesOTHER | 1 | Apr 21, 2022 | clinicaltrials |
| NCT02178709 | A Phase II Study of Neoadjuvant FOLFIRINOX | completed | Phase 2 | 48 | Indiana UniversityOTHER | 1 | Apr 19, 2022 | clinicaltrials |
| NCT02810418 | Mesothelin-Targeted Immunotoxin LMB-100 Alone or in Combination With Nab-Paclitaxel in People With Previously Treated Metastatic and/or Locally Advanced Pancreatic Ductal Adenocarcinoma and Mesothelin Expressing Solid Tumors | completed | Phase 1 / Phase 2 | 40 | National Cancer Institute (NCI)NIH | 1 | Mar 15, 2022 | clinicaltrials |
| NCT01360593 | Gemcitabine/Capecitabine Followed by SBRT in Pancreatic Adenocarcinoma | completed | Phase 2 | 35 | David A. Clump, MD, PhDOTHER | 1 | Mar 8, 2022 | clinicaltrials |
| NCT02131493 | S-1 and and Gemcitabine vs Gemcitabine Alone as Adjuvant Chemotherapy for Patients With Resected Pancreatic Cancer | completed | Phase 2 | 80 | Zhejiang UniversityOTHER | 1 | Mar 2, 2022 | clinicaltrials |
| NCT00617708 | S0727 Gemcitabine Hydrochloride and Erlotinib Hydrochloride With or Without Monoclonal Antibody Therapy in Treating Patients With Metastatic Pancreatic Cancer That Cannot Be Removed By Surgery | completed | Phase 1 / Phase 2 | 134 | National Cancer Institute (NCI)NIH | 1 | Feb 8, 2022 | clinicaltrials |
| NCT04790695 | Single Patient Protocol for an NRG1 Fusion Positive Metastatic Pancreatic Cancer Patient Using Seribantumab | completed | Phase 2 | 1 | Ottawa Hospital Research InstituteOTHER | 1 | Jan 12, 2022 | clinicaltrials |
| NCT02125136 | Trial to Investigate Intensified Neoadjuvant Chemotherapy in Locally Advanced Pancreatic Cancer(NEOLAP) | completed | Phase 2 | 168 | AIO-Studien-gGmbHOTHER | 1 | Dec 15, 2021 | clinicaltrials |
| NCT02259725 | Regorafenib in Treating Patients With Advanced or Metastatic Neuroendocrine Tumors | completed | Phase 2 | 3 | University of Southern CaliforniaOTHER | 1 | Dec 15, 2021 | clinicaltrials |
| NCT01303172 | A Trial Comparing Gemcitabine With and Without IMM-101 in Advanced Pancreatic Cancer | completed | Phase 2 | 110 | Immodulon Therapeutics LtdINDUSTRY | 5 | Nov 10, 2021 | clinicaltrials |
| NCT01660711 | A Pilot Study of Pre- and Post-surgery Chemotherapy With mFOLFIRINOX in Localized, Resectable Pancreatic Adenocarcinoma | completed | Phase 2 | 22 | Endeavor HealthOTHER | 1 | Nov 8, 2021 | clinicaltrials |
| NCT03410914 | Intra-operative Application of HEMOPATCH to the Pancreatic Stump to Prevent Post-operative Pancreatic Fistula Following Distal Pancreatectomy(PATCH-DP) | completed | Phase 2 | 52 | Sunnybrook Health Sciences CentreOTHER | 1 | Nov 3, 2021 | clinicaltrials |
| NCT03023722 | Phase II Anetumab Ravtansine in Pre-treated Mesothelin-expressing Pancreatic Cancer | completed | Phase 2 | 18 | Yale UniversityOTHER | 1 | Oct 28, 2021 | clinicaltrials |
| NCT03738787 | Treatment of the Pancreatic Stump With Neoprene®-Based Glue After High-risk Pancreatoduodenectomy | completed | Phase 2 | 40 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | Oct 5, 2021 | clinicaltrials |
| NCT00112580 | MDX-010 in Treating Patients With Stage IV Pancreatic Cancer That Cannot Be Removed By Surgery | completed | Phase 2 | 27 | Bristol-Myers SquibbINDUSTRY | 1 | Sep 27, 2021 | clinicaltrials |
| NCT03261947 | A Study to Evaluate the Safety, Tolerability, and Activity of TAK-931 in Participants With Metastatic Pancreatic Cancer, Metastatic Colorectal Cancer, and Other Advanced Solid Tumors | completed | Phase 2 | 101 | Millennium Pharmaceuticals, Inc.INDUSTRY | 2 | Sep 20, 2021 | clinicaltrials |
| NCT00010166 | Gemcitabine and Radiation Therapy in Treating Patients With Cancer of the Pancreas | completed | Phase 2 | 26 | Wake Forest University Health SciencesOTHER | 1 | Sep 9, 2021 | clinicaltrials |
| NCT00025168 | Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Unresectable Pancreatic Cancer | completed | Phase 2 | 20 | Wake Forest University Health SciencesOTHER | 1 | Sep 9, 2021 | clinicaltrials |
| NCT00041639 | Safety Study of 90Y-hMN14 to Treat Pancreatic Cancer | completed | Phase 1 / Phase 2 | 75 | Gilead SciencesINDUSTRY | 4 | Aug 19, 2021 | clinicaltrials |
| NCT00597129 | Safety and Efficacy Study of 90Y-hPAM4 at Different Doses | completed | Phase 1 / Phase 2 | 21 | Gilead SciencesINDUSTRY | 1 | Aug 19, 2021 | clinicaltrials |
| NCT00603863 | Safety and Efficacy Study of Different Doses of 90Y-hPAM4 Combined With Gemcitabine in Pancreatic Cancer | completed | Phase 1 / Phase 2 | 80 | Gilead SciencesINDUSTRY | 1 | Aug 16, 2021 | clinicaltrials |
| NCT01631552 | Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer | completed | Phase 1 / Phase 2 | 515 | Gilead SciencesINDUSTRY | 1 | Aug 12, 2021 | clinicaltrials |
| NCT02807844 | Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies | completed | Phase 1 / Phase 2 | 141 | Novartis PharmaceuticalsINDUSTRY | 11 | Aug 11, 2021 | clinicaltrials |
| NCT01666730 | Metformin Plus Modified FOLFOX 6 in Metastatic Pancreatic Cancer | completed | Phase 2 | 50 | Case Comprehensive Cancer CenterOTHER | 1 | Aug 10, 2021 | clinicaltrials |
| NCT01465659 | Temozolomide and Pazopanib Hydrochloride in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors That Cannot Be Removed By Surgery | completed | Phase 1 / Phase 2 | 29 | Northwestern UniversityOTHER | 1 | Aug 5, 2021 | clinicaltrials |
| NCT03189953 | 68Ga-NODAGA-exendin-4 PET/CT for Diagnostic Imaging in AHH(GLP-1-AHH) | completed | Phase 1 / Phase 2 | 56 | Radboud University Medical CenterOTHER | 0 | Jun 16, 2021 | clinicaltrials |
| NCT03188991 | Intracystic Injection of NanoPac® in Subjects With Mucinous Cystic Pancreatic Neoplasms | completed | Phase 2 | 20 | NanOlogy, LLCINDUSTRY | 1 | Jun 14, 2021 | clinicaltrials |
| NCT00031694 | Paclitaxel and Bryostatin 1 in Treating Patients With Advanced Pancreatic Cancer | completed | Phase 2 | 19 | National Cancer Institute (NCI)NIH | 1 | Jun 11, 2021 | clinicaltrials |
| NCT01459614 | Gemcitabine/Taxotere/Xeloda (GTX) With Cisplatin in Subjects With Metastatic Pancreatic Cancer | completed | Phase 2 | 44 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | May 19, 2021 | clinicaltrials |
| NCT02562898 | Ibrutinib Combined With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer | completed | Phase 1 / Phase 2 | 18 | Margaret TemperoOTHER | 1 | May 6, 2021 | clinicaltrials |
| NCT01077986 | Everolimus, Cetuximab and Capecitabine in Patients With Metastatic Pancreatic Cancer | completed | Phase 1 / Phase 2 | 35 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)OTHER | 1 | Apr 21, 2021 | clinicaltrials |
| NCT01210911 | Metformin Combined With Chemotherapy for Pancreatic Cancer(GEM) | completed | Phase 2 | 120 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)OTHER | 1 | Apr 21, 2021 | clinicaltrials |
| NCT02311361 | Immune Checkpoint Inhibition (Tremelimumab and/or MEDI4736) in Combination With Radiation Therapy in Patients With Unresectable Pancreatic Cancer | completed | Phase 1 / Phase 2 | 65 | National Cancer Institute (NCI)NIH | 1 | Apr 20, 2021 | clinicaltrials |
| NCT00521404 | Open-label Study of CS-1008 for Subjects With Untreated and Unresectable Pancreatic Cancer | completed | Phase 2 | 65 | Daiichi SankyoINDUSTRY | 1 | Apr 8, 2021 | clinicaltrials |
| NCT01251640 | Combination With Gemcitabine in Advanced Pancreatic Cancer(BAGPAC) | completed | Phase 1 / Phase 2 | 90 | BayerINDUSTRY | 9 | Apr 8, 2021 | clinicaltrials |
| NCT00112658 | Combination Chemotherapy as First-Line Therapy in Treating Patients With Metastatic Pancreatic Cancer | completed | Phase 2 / Phase 3 | 342 | UNICANCEROTHER | 1 | Mar 8, 2021 | clinicaltrials |
| NCT00376948 | Genistein, Gemcitabine, and Erlotinib in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer | completed | Phase 2 | 20 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Mar 1, 2021 | clinicaltrials |
| NCT01838317 | A Phase II Study of Pioglitazone for Patients With Cancer of the Pancreas | completed | Phase 2 | 14 | University of Texas Southwestern Medical CenterOTHER | 1 | Mar 1, 2021 | clinicaltrials |
| NCT03415802 | Efficacy and Safety of Nab-Paclitaxel Plus S-1 in the First-line Treatment of Advanced Pancreatic Cancer | completed | Phase 2 | 32 | Aiping ZhouUNKNOWN | 1 | Feb 1, 2021 | clinicaltrials |
Data updated 23 days agoSource updated Sep 10, 2022source: clinicaltrials